ABSTRACT
Introduction: Patients with RA are at a higher risk of developing CV diseases than the general population. The precise mechanisms are still unknown. We evaluated the associations between 8 plasma growth factors (GFs) (angiopoietin-2, EGF, HB-EGF, PLGF, TGF-α, VEGFa, VEGFc, and VEGFd) and subclinical arteriosclerosis in RA patients. Materials and methods: A total of 199 patients with RA treated at the Hospital Universitari Sant Joan de Reus (Spain) between 2011 and 2015 were included in this cross-sectional study. Carotid intima media thickness (cIMT), carotid plaque presence (cPP) and pulse wave velocity (PWV) were measured. GFs were measured with Bio-Plex Pro Human Cancer Biomarker Panel 2 (Bio-Rad). Multivariate models and partial least square discriminant analysis (PLS-DA) were used for analysis (RStudio, version 4.0.1). Results: Multivariate models showed that angiopoietin-2 was associated with cPP and PWV in the overall cohort (OR = 1.53 and ß = 0.20, respectively). VEGFc (ß = 0.29), VEGFa (ß = 0.26) and HB-EGF (ß = 0.22) were also associated with PWV. VEGFa (OR = 2.36), VEGFd (OR = 2.29), EGF (OR = 2.62), PLGF (OR = 2.54), and HB-EGF (OR = 2.24) were associated with cPP in men. According to PLS-DA, GFs were able to distinguish between patients with and without cPP in the overall cohort, male cohort, and female cohort. In women, angiopoietin-2 was associated with PWV (ß = 0.18). Conclusions: The selected GFs were closely related to atherosclerosis in patients with RA and are potential predictors of CV disease in patients with RA.
ABSTRACT
BACKGROUND AND AIM: Triglyceride-rich lipoproteins (TRLs) can have an important role in atherosclerosis development due to their size and ability to penetrate the endothelium. While high plasma triglyceride (TG) levels and chronic inflammation are relevant in metabolic diseases, it remains unclear whether TGs are atherogenic or which TRL-TG-derived metabolites are responsible for inflammation. Here, we aimed to study the lipidome modifications of TRL particles enriched in TG in patients with hyperlipidemia and their associations with a proinflammatory status both in vivo and in vitro. METHODS: Using proton nuclear magnetic resonance (1 H-NMR), we analysed the plasma levels of glycoprotein acetyls and the TRL lipidomic profile of 307 patients with dyslipidemia. THP-1-derived macrophages were used as an in vitro model to explore the molecular inflammatory effects mediated by TRL. RESULTS: In vivo, higher TRL-TG levels were associated with higher circulating levels of NMR-measured glycoproteins (Glyc-A, Glyc-B and Glyc-F; p < .001). Lipidomic analysis showed that TRL-TG enrichment led to decreased cholesterol and phospholipid content (p < .01), an increase in omega-9, and a decrease in saturated fatty acids (p < .001). THP-1 macrophages exposed to increasing TRL particle concentrations augmented the secretion of IL-1ß and TNF-α, which varied based on particle composition. Particles with higher cholesterol and phospholipid contents exerted higher cytokine secretion. The activation of MAPK, Akt/NFκB, and caspase-1 was concurrent with this proinflammatory response. CONCLUSIONS: High TRL-TG levels are associated with a higher systemic inflammatory status and increased particle concentrations. In vitro, higher particle numbers increase proinflammatory cytokine secretion, with cholesterol and phospholipid-rich TRL being more proinflammatory.
Subject(s)
Hyperlipidemias , Lipidomics , Humans , Lipoproteins , Triglycerides , Cholesterol , Inflammation , Phospholipids , CytokinesABSTRACT
Rheumatoid arthritis (RA) is associated with problems beyond the joints such as cardiovascular (CV) disease. MicroRNA-24, -146 and -Let7a are associated with carotid plaque presence in RA patients. We evaluated whether these microRNAs were involved in the inflammatory state of RA, and we studied their gene targets to understand their role in inflammation and atherosclerosis. A total of 199 patients with RA were included. Inflammatory variables such as disease activity score 28 (DAS28) and erythrocyte sedimentation rate (ESR) were quantified. MicroRNAs were extracted from plasma and quantified with qPCR. Multivariate models and classification methods were used for analysis. The multivariate models showed that diminished expression of microRNA-146 was associated with inferior levels of DAS28-ESR, and the decreased expression of microRNA-24, -146 and -Let7a were associated with lowered ESR in the overall cohort. When microRNAs were evaluated globally, a global increase was associated with increased DAS28-ESR and ESR in the overall cohort. Sex-stratified analyses showed different associations of these microRNAs with the inflammatory variables. Finally, random forest models showed that microRNAs have a pivotal role in classifying patients with high and low inflammation. Plasmatic expressions of microRNA-24, -146 and -Let7a were associated with inflammatory markers of RA. These microRNAs are associated with both inflammation and atherosclerosis and are potential therapeutic targets for RA.
Subject(s)
Arthritis, Rheumatoid , Atherosclerosis , Cardiovascular Diseases , MicroRNAs , Plaque, Atherosclerotic , Humans , MicroRNAs/genetics , C-Reactive Protein/metabolism , Inflammation/genetics , Inflammation/complications , Plaque, Atherosclerotic/genetics , Plaque, Atherosclerotic/complications , Atherosclerosis/complications , Cardiovascular Diseases/complicationsABSTRACT
BACKGROUND AND AIM: Circulating biomarkers of metabolic and cardiovascular diseases can help in the early detection and prevention of those diseases. Using proton nuclear magnetic resonance (1H-NMR), we aimed to study the plasma levels of low-molecular-weight metabolites (LMWMs) in a cohort of 307 patients with metabolic diseases to assess their relationships with type-2 diabetes (T2D) and incident atherosclerotic cardiovascular disease (ASCVD). METHODS: We conducted a cross-sectional and prospective study. We included 307 patients attending the Lipid Unit of our University Hospital for the treatment of the following metabolic disturbances and associated disorders: T2D (73.9%), obesity (58.7%), and hypertension (55.1%). 1H-NMR was used to study the plasma levels of 13 LMWMs. LMWM serum concentrations were evaluated in patients with and without T2D. and the correlations with several parameters and their associations with T2D were analyzed. The association between LMWM levels at baseline and the development of ASCVD in patients with T2D after 10 years of follow-up was also evaluated. RESULTS: Among the LMWMs measured, the branched-chain amino acids (BCAAs) valine, leucine and isoleucine showed a positive association with several clinical and lipid-related biochemical parameters and inflammatory markers (p < 0.05). Likewise, these three BCAAS were associated with diabetes even after adjusting for covariates (p < 0.05). During the follow-up period of 10 years, 29 of the 185 patients with diabetes at baseline (15.68%) developed ASCVD. After adjusting for clinical covariates, baseline levels of valine and alanine were associated with the development of ASCVD (p < 0.05). CONCLUSION: Overall, our results indicated that plasma levels of LMWMs measured by 1H-NMR could be potential biomarkers associated with T2D. Moreover, alanine and valine can help in the early detection of the cardiovascular risk associated with this metabolic disease.
Subject(s)
Atherosclerosis , Cardiovascular Diseases , Diabetes Mellitus, Type 2 , Humans , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/epidemiology , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/epidemiology , Cross-Sectional Studies , Prospective Studies , Alanine , Atherosclerosis/diagnosis , Atherosclerosis/epidemiology , LipidsABSTRACT
Atherosclerosis is a chronic inflammatory disease caused by the accumulation of cholesterol in the intima. Proprotein convertase subtilisin/kexin type 9 inhibitors (iPCSK9) can reduce low-density lipoprotein (LDL) cholesterol levels by 60%, but there is still no evidence that they can lower markers of systemic inflammation such as high-sensitivity C-reactive protein (hsCRP). Acute-phase serum glycoproteins are upregulated in the liver during systemic inflammation, and their role as inflammatory biomarkers is under clinical evaluation. In this observational study, we evaluate the effects of iPCSK9 on glycoproteins (Glyc) A, B and F. Thirty-nine patients eligible for iPCSK9 therapy were enrolled. One sample before and after one to six months of iPCSK9 therapy with alirocumab was obtained from each patient. Lipids, apolipoproteins, hsCRP and PCSK9 levels were measured by biochemical analyses, and the lipoprotein and glycoprotein profiles were measured by 1H nuclear magnetic resonance (1H-NMR). The PCSK9 inhibitor reduced total (36.27%, p < 0.001), LDL (55.05%, p < 0.001) and non-high-density lipoprotein (HDL) (45.11%, p < 0.001) cholesterol, apolipoprotein (apo) C-III (10%, p < 0.001), triglycerides (9.92%, p < 0.001) and glycoprotein signals GlycA (11.97%, p < 0.001), GlycB (3.83%, p = 0.017) and GlycF (7.26%, p < 0.001). It also increased apoA-I (2.05%, p = 0.043) and HDL cholesterol levels (11.58%, p < 0.001). Circulating PCSK9 levels increased six-fold (626.28%, p < 0.001). The decrease in Glyc signals positively correlated with the decrease in triglycerides and apoC-III. In conclusion, in addition to LDL cholesterol, iPCSK9 therapy also induces a reduction in systemic inflammation measured by 1H-NMR glycoprotein signals, which correlates with a decrease in triglycerides and apoC-III.
Subject(s)
Cardiovascular Diseases , Proprotein Convertase 9 , Humans , Proprotein Convertase 9/metabolism , PCSK9 Inhibitors , Apolipoprotein C-III , Cardiovascular Diseases/etiology , C-Reactive Protein , Proton Magnetic Resonance Spectroscopy , Risk Factors , Cholesterol , Cholesterol, LDL , Triglycerides , Magnetic Resonance Spectroscopy/adverse effects , Lipoproteins , Inflammation/drug therapy , Inflammation/complications , Anti-Inflammatory Agents , Glycoproteins , Heart Disease Risk FactorsABSTRACT
OBJECTIVE: Patients with RA present increased risk of cardiovascular (CV) disease compared with the general population. Moreover, CV risk factors that have a causal relationship with atherosclerosis do not seem to fully explain the accelerated process that they exhibit. We evaluated the association of a 10 microRNAs panel with surrogate markers of subclinical arteriosclerosis [carotid intima-media thickness (cIMT), carotid plaque presence (cPP), pulse wave velocity (PWV) and distensibility] in a cohort of RA patients. MATERIAL AND METHODS: A total of 199 patients with RA were included. Surrogate markers of arteriosclerosis were measured with My Lab 60 X-Vision sonographer. MicroRNAs were extracted from plasma and quantified with qPCR. Multivariate models and classification methods were performed. RESULTS: Multivariate models showed that microRNAs-24 (ß = 15.48), 125a (ß = 9.93), 132 (ß = 11.52), 146 (ß = 15.12), 191 (ß = 13.25) and 223 (ß = 13.30) were associated with cIMT globally. MicroRNA-24 [odds ratio (OR) = 0.41], 146 (OR = 0.36) and Let7a (OR = 0.23) were associated with cPP in men. Including the microRNAs in a partial least square discriminant analysis model properly classified men with and without cPP. MicroRNA-96 (ß = -0.28) was associated with PWV in male patients. Finally, several miRNAs were also associated with cIMT, cPP and arterial stiffness in the high DAS28 group and in the earlier tertile groups of disease duration. CONCLUSION: Plasmatic expression of microRNA-24, 96, 103, 125a, 132, 146, 191, 223 and Let7a were associated with surrogate markers of CV disease and could be predictors of CV risk in patients with RA.
Subject(s)
Arthritis, Rheumatoid , Atherosclerosis , Cardiovascular Diseases , MicroRNAs , Humans , Male , Carotid Intima-Media Thickness , Risk Factors , Cardiovascular Diseases/epidemiology , Pulse Wave Analysis/adverse effects , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/genetics , Atherosclerosis/etiology , BiomarkersABSTRACT
To validate in a cohort of 214 rheumatoid arthritis patients a panel of 10 plasmatic microRNAs, which we previously identified and that can facilitate earlier diagnosis of cardiovascular disease in rheumatoid arthritis patients. We identified 10 plasma miRs that were downregulated in male rheumatoid arthritis patients and in patients with acute myocardial infarction compared to controls suggesting that these microRNAs could be epigenetic biomarkers for cardiovascular disease in rheumatoid arthritis patients. Six of those microRNAs were validated in independent plasma samples from 214 rheumatoid arthritis patients and levels of expression were associated with surrogate markers of cardiovascular disease (carotid intima-media thickness, plaque formation, pulse wave velocity and distensibility) and with prior cardiovascular disease. Multivariate analyses adjusted for traditional confounders and treatments showed that decreased expression of microRNA-425-5p in men and decreased expression of microRNA-451 in women were significantly associated with increased (ß = 0.072; p = 0.017) and decreased carotid intima-media thickness (ß = -0.05; p = 0.013), respectively. MicroRNA-425-5p and microRNA-451 also increased the accuracy to discriminate patients with pathological carotid intima-media thickness by 1.8% (p = 0.036) in men and 3.5% (p = 0.027) in women, respectively. In addition, microRNA-425-5p increased the accuracy to discriminate male patients with prior cardiovascular disease by 3% (p = 0.008). Additionally, decreased expression of microRNA-451 was significantly associated with decreased pulse wave velocity (ß = -0.72; p = 0.035) in overall rheumatoid arthritis population. Distensibility showed no significant association with expression levels of the microRNAs studied. We provide evidence of a possible role of microRNA-425-5p and microRNA-451 as useful epigenetic biomarkers to assess cardiovascular disease risk in patients with rheumatoid arthritis.
Subject(s)
Arthritis, Rheumatoid , MicroRNAs , Adult , Female , Humans , Male , Middle Aged , Pulse Wave AnalysisABSTRACT
High plasma triglyceride (TG) levels and chronic inflammation are important factors related to metabolic-associated fatty liver disease in patients at cardiovascular risk. Using nuclear magnetic resonance (1H-NMR), we aimed to study the triglyceride-rich lipoprotein (TRL) and acute-phase glycoprotein profiles of a cohort of patients with metabolic disease and their relationship with fatty liver. Plasma samples of 280 patients (type 2 diabetes, 81.1%; obesity, 63.3%; and metabolic syndrome, 91.8%) from the University Hospital Lipid Unit were collected for the measurement of small, medium and large TRL particle numbers and sizes and glycoprotein profiles (Glyc-A and Glyc-B) by 1H-NMR. Liver function parameters, including the fatty liver index (FLI) and fibrosis-4 (FIB-4) score, were assessed. Hepatic echography assessment was performed in 100 patients, and they were followed up for 10 years. TRL particle concentrations showed a strong positive association with Glyc-A and Glyc-B (ρ=0.895 and ρ=0.654, p<0.001, respectively) and with the liver function-related proteins ALT ρ=0.293, p<0.001), AST (ρ=0.318, p<0.001) and GGT (ρ=0.284, p<0.001). Likewise, TRL concentrations showed a positive association with FLI (ρ=0.425, p<0.001) but not with FIB-4. During the follow-up period of 10 years, 18 new cases of steatosis were observed among 64 patients who were disease-free at baseline. Baseline TRL particle numbers and glycoprotein levels were associated with the new development of metabolic-associated fatty liver disease (MAFLD) (AUC=0.692, p=0.018 and AUC=0.669, p=0.037, respectively). Overall, our results indicated that TRL number and acute-phase glycoproteins measured by 1H-NMR could be potential biomarkers of the development of hepatic steatosis in patients at metabolic risk.
Subject(s)
Diabetes Mellitus, Type 2/metabolism , Glycoproteins/metabolism , Lipoproteins/metabolism , Metabolic Syndrome/metabolism , Non-alcoholic Fatty Liver Disease/metabolism , Obesity/metabolism , Triglycerides/metabolism , Aged , Alanine Transaminase/metabolism , Aspartate Aminotransferases/metabolism , Female , Humans , Male , Middle Aged , Non-alcoholic Fatty Liver Disease/diagnostic imaging , Proton Magnetic Resonance Spectroscopy , UltrasonographyABSTRACT
Fatty acids are essential to cell functionality and may exert diverging vascular effects including migration, proliferation, oxidative stress, and inflammation. This study examined the effect of palmitate on human coronary artery smooth muscle cell (HCASMC) function. An in vitro wound-healing assay indicated that palmitate decreased HCASMC migration in dose- and time-dependent manners. Furthermore, bromodeoxyuridine incorporation assays indicated that palmitate decreased HCASMC proliferation in a dose-response manner. Palmitate also increased reactive oxygen species formation, malondialdehyde content, and intracellular lipid droplets accompanied with increased fatty acid binding protein 4 expression. Moreover, palmitate induced gene expression (monocyte chemoattractant protein 1, matrix metalloproteinase-2, IL-1ß, IL-6, IL-8, and TNF-α) and intracellular protein content (plasminogen activator inhibitor-1 and urokinase plasminogen activator) of inflammatory mediators. Finally, we showed that palmitate activates the transcription factor Nrf2 and the upstream kinases ERK1/2 and Akt in HCASMCs. The inhibitor of Nrf2, trigonelline, significantly attenuated palmitate-induced HCASMC expression of the Nrf2 target gene NQO1. These findings indicate that palmitate might be critically related to HCASMC function by slowing cell migration and proliferation and inducing lipid-laden cells, oxidative stress, and inflammation in part by activation of the Nrf2 transcription factor. Palmitate's activation of proinflammatory Nrf2 signaling may represent a novel mechanism mediating the proatherogenic actions of saturated fatty acids.
Subject(s)
Cell Movement/physiology , Inflammation Mediators/metabolism , Myocytes, Smooth Muscle/metabolism , NF-E2-Related Factor 2/physiology , Oxidative Stress/physiology , Palmitates/toxicity , Cell Movement/drug effects , Cell Proliferation/drug effects , Cell Proliferation/physiology , Coronary Vessels/drug effects , Coronary Vessels/metabolism , Coronary Vessels/pathology , Dose-Response Relationship, Drug , Humans , Myocytes, Smooth Muscle/drug effects , Myocytes, Smooth Muscle/pathology , Oxidative Stress/drug effects , Signal Transduction/drug effects , Signal Transduction/physiologyABSTRACT
While the impact of very low concentrations of low-density lipoprotein cholesterol (LDL-C) on cardiovascular prevention is very reassuring, it is intriguing to know what effect these extremely low LDL-C concentrations have on lipid homoeostasis. The evidence supporting the safety of extremely low LDL levels comes from genetic studies and clinical drug trials. Individuals with lifelong low LDL levels due to mutations in genes associated with increased LDL-LDL receptor (LDLR) activity reveal no safety issues. Patients achieving extremely low LDL levels in the IMPROVE-IT and FOURIER, and the PROFICIO and ODYSSEY programs seem not to have an increased prevalence of adverse effects. The main concern regarding extremely low LDL-C plasma concentrations is the adequacy of the supply of cholesterol, and other molecules, to peripheral tissues. However, LDL proteomic and kinetic studies reaffirm that LDL is the final product of endogenous lipoprotein metabolism. Four of 5 LDL particles are cleared through the LDL-LDLR pathway in the liver. Given that mammalian cells have no enzymatic systems to degrade cholesterol, the LDL-LDLR pathway is the main mechanism for removal of cholesterol from the body. Our focus, therefore, is to review, from a physiological perspective, why such extremely low LDL-C concentrations do not appear to be detrimental. We suggest that extremely low LDL-C levels due to increased LDLR activity may be a surrogate of adequate LDL-LDLR pathway function.
Subject(s)
Anticholesteremic Agents/therapeutic use , Cardiovascular Diseases/metabolism , Cholesterol, LDL/antagonists & inhibitors , Lipoproteins, LDL/metabolism , Proteomics/methods , Receptors, LDL/metabolism , Animals , Cardiovascular Diseases/blood , Cardiovascular Diseases/genetics , Cholesterol/blood , Cholesterol/metabolism , Cholesterol, LDL/blood , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Lipoproteins, LDL/blood , Lipoproteins, LDL/genetics , Receptors, LDL/blood , Receptors, LDL/geneticsSubject(s)
Cholesterol, HDL/blood , Cholesterol/blood , Diabetes Mellitus/blood , Lipoproteins/blood , Triglycerides/blood , Adult , Female , Humans , MaleABSTRACT
The composition and structure of the extracellular matrix (ECM) in the vascular wall and in the atherosclerotic plaque are important factors that determine plaque stability. Statins can stabilize atherosclerotic plaques by modulating ECM protein expression. Fibulins are important components of the ECM. We evaluated the in vitro effect of simvastatin on the expression of fibulin-1, -2, -4 and -5 in human coronary artery smooth muscle cells (SMCs) and the mechanisms involved. Cells were incubated with simvastatin (0.05-1 µM), mevalonate (100 and 200 µM), geranylgeranyl pyrophosphate (GGPP) (15 µM), farnesyl pyrophosphate (FPP) (15 µM), the Rho kinase (ROCK) inhibitor Y-27632 (15 and 20 µM), the Rac-1 inhibitor (another member of Rho family) NSC23766 (100 µM), arachidonic acid (a RhoA/ROCK activator, 25-100 µM) and other fatty acids that are not activators of RhoA/ROCK (25-100 µM). Gene expression was analyzed by quantitative real-time PCR, and fibulin protein levels were analyzed by western blotting and ELISA. Simvastatin induced a significant increase in mRNA and protein levels of fibulin-2 at 24 hours of incubation (p<0.05), but it did not affect fibulin-1, -4, and -5 expression. Mevalonate and GGPP were able to reverse simvastatin's effect, while FPP did not. In addition, Y-27632, but not NSC23766, significantly increased fibulin-2 expression. Furthermore, activation of the RhoA/ROCK pathway with arachidonic acid decreased fibulin-2 mRNA. Simvastatin increased mRNA levels and protein expression of the ECM protein fibulin-2 through a RhoA and Rho-Kinase-mediated pathway. This increase could affect the composition and structure of the ECM.
Subject(s)
Calcium-Binding Proteins/metabolism , Coronary Vessels/drug effects , Extracellular Matrix Proteins/metabolism , Muscle, Smooth, Vascular/drug effects , Myocytes, Smooth Muscle/drug effects , Signal Transduction/drug effects , Simvastatin/pharmacology , rho-Associated Kinases/metabolism , rhoA GTP-Binding Protein/metabolism , Cell Line , Coronary Vessels/metabolism , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Muscle, Smooth, Vascular/metabolism , Myocytes, Smooth Muscle/metabolismABSTRACT
OBJECTIVE: The tissue-specific expression profiles of genes within the APOA1/C3/A4/A5 cluster play an important role in lipid metabolism regulation. We hypothesize that the tissue-specific expression of the APOA1/C3/A4/A5 gene cluster will show an inverse pattern with DNA methylation, and that repression in non- or low-expressing tissue, such as the intestine, can be reversed using epigenetic drugs. METHODS AND RESULTS: We analyzed DNA samples from different human adult tissues (liver, intestine, leukocytes, brain, kidney, pancreas, muscle and sperm) using the Infinium HumanMethyation450 BeadChip array. DNA methylation profiles in APOA1/C3/A4/A5 gene cluster were confirmed by bisulfite PCR and pyrosequencing. To determine whether the observed tissue-specific methylation was associated with the expression profile we exposed intestinal TC7/Caco-2 cells to the demethylating agent 5-Aza-2'-deoxycytidine and monitored intestinal APOA1/C3/A4/A5 transcript re-expression by RT-qPCR. The promoters of APOA1, APOC3 and APOA5 genes were less methylated in liver compared to other tissues, and APOA4 gene was highly methylated in most tissues and partially methylated in liver and intestine. In TC7/Caco-2 cells, 5-Aza-2'-deoxycytidine treatment induced a decrease between 37 and 24% in the methylation levels of APOA1/C3/A4/A5 genes and a concomitant re-expression mainly in APOA1, APOA4 and APOA5 genes ranging from 22 to 600%. CONCLUSIONS: We have determined the methylation patterns of the APOA1/C3/A4/A5 cluster that may be directly involved in the transcriptional regulation of this cluster. DNA demethylation of intestinal cells increases the RNA levels especially of APOA1, APOA4 and APOA5 genes.
Subject(s)
Apolipoprotein A-I/genetics , Apolipoprotein C-III/genetics , Apolipoproteins A/genetics , DNA Methylation , Liver/metabolism , Multigene Family , Apolipoprotein A-V , Biopsy , Brain/metabolism , Caco-2 Cells , Cell Line, Tumor , Humans , Intestinal Mucosa/metabolism , Kidney/metabolism , Leukocytes/metabolism , Male , Muscles/metabolism , Oligonucleotide Array Sequence Analysis , Pancreas/metabolism , Spermatozoa/metabolismABSTRACT
PURPOSE: The migration and proliferation of vascular smooth muscle cells play crucial roles in the development of atherosclerotic lesions. This study examined the effects of fatty acid binding protein 4 (FABP4), an adipokine that is associated with cardiovascular risk, endothelial dysfunction and proinflammatory effects, on the migration and proliferation of human coronary artery smooth muscle cells (HCASMCs). METHODS AND RESULTS: A DNA 5-bromo-2'-deoxy-uridine (BrdU) incorporation assay indicated that FABP4 significantly induced the dose-dependent proliferation of HCASMCs with a maximum stimulatory effect at 120 ng/ml (13% vs. unstimulated cells, p<0.05). An anti-FABP4 antibody (40 ng/ml) significantly inhibited the induced cell proliferation, demonstrating the specificity of the FABP4 proliferative effect. FABP4 significantly induced HCASMC migration in a dose-dependent manner with an initial effect at 60 ng/ml (12% vs. unstimulated cells, p<0.05). Time-course studies demonstrated that FABP4 significantly increased cell migration compared with unstimulated cells from 4 h (23%vs. 17%, p<0.05) to 12 h (74%vs. 59%, p<0.05). Pretreatment with LY-294002 (5 µM) and PD98059 (10 µM) blocked the FABP4-induced proliferation and migration of HCASMCs, suggesting the activation of a kinase pathway. On a molecular level, we observed an up-regulation of the MAPK pathway without activation of Akt. We found that FABP4 induced the active forms of the nuclear transcription factors c-jun and c-myc, which are regulated by MAPK cascades, and increased the expression of the downstream genes cyclin D1 and MMP2, CCL2, and fibulin 4 and 5, which are involved in cell cycle regulation and cell migration. CONCLUSIONS: These findings indicate a direct effect of FABP4 on the migration and proliferation of HCASMCs, suggesting a role for this adipokine in vascular remodelling. Taken together, these results demonstrate that the FABP4-induced DNA synthesis and cell migration are mediated primarily through a MAPK-dependent pathway that activates the transcription factors c-jun and c-myc in HCASMCs.
Subject(s)
Cell Movement/physiology , Cell Proliferation , Fatty Acid-Binding Proteins/physiology , MAP Kinase Signaling System , Muscle, Smooth, Vascular/cytology , Cells, Cultured , Enzyme Activation , Humans , Muscle, Smooth, Vascular/enzymology , Muscle, Smooth, Vascular/metabolism , Real-Time Polymerase Chain ReactionABSTRACT
Several transporter proteins regulate intestinal cholesterol absorption. Of these proteins, NPC1L1 is a major contributor to this process. Fatty acids (FAs) modulate cholesterol absorption by a mechanism that remains unknown. We evaluate the effect of saturated fatty acids (SFAs), monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs) on the expression of NPC1L1 and others proteins associated with cholesterol absorption (SR-BI, ABCG5, ABCG8, ABCA1, CAV-1, ANX-2) in human enterocytes in vitro. The role of SREBPs, PPARs, LXR and RXR in this process was also investigated. Caco-2/TC-7 enterocytes were incubated for 24 h with a wide range of concentrations of FA-bovine serum albumin (50-300 microM). Gene expression was analyzed by quantitative real-time PCR. The NPC1L1 protein present in enterocyte membranes was analyzed using Western blot. NPC1L1 mRNA levels were reduced 35-58% by the n-3 PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (P<.05). Linoleic acid (n-6), palmitic acid and oleic acid did not affect NPC1L1 mRNA expression. ABCA1 mRNA levels were reduced 44-70% by n-6 arachidonic acid and 43-55% by n-3 EPA (P<.05). LXR and LXR+RXR agonists decreased NPC1L1 mRNA expression by 28% and 57%, respectively (P<.05). A concentration of 200 microM of EPA and DHA decreased NPC1L1 protein expression in enterocyte membranes by 58% and 59%, respectively. We have demonstrated that the PUFAs n-3 EPA and DHA down-regulate NPC1L1 mRNA expression. In addition, PUFAs also down-regulate NPC1L1 protein expression in enterocyte membranes. LXR and RXR activation induced a similar repression effect. The lipid-lowering effect of n-3 PUFAs could be mediated in part by their action at the NPC1L1 gene level.
Subject(s)
Cholesterol/metabolism , Fatty Acids, Unsaturated/metabolism , Gene Expression Regulation , Membrane Proteins/metabolism , Absorption , Caco-2 Cells , Docosahexaenoic Acids/metabolism , Eicosapentaenoic Acid/metabolism , Enterocytes/metabolism , Fatty Acids, Monounsaturated/metabolism , Humans , Intestinal Mucosa/metabolism , Linoleic Acid/chemistry , Membrane Transport Proteins , Models, Biological , Oleic Acid/chemistry , Palmitic Acid/metabolismABSTRACT
Introducción. La absorción intestinal de colesterol está regulada por diversas proteínas transportadoras, donde NPC1L1 desempeña un papel crucial. Los ácidos grasos (AG) modulan la absorción de colesterol por un mecanismo desconocido. Objetivos. Evaluar los efectos de los AG saturados (AGS), monoinsaturados (AGMI) y poliinsaturados (AGPI) sobre la expresión deNPC1L1 y estudiar su posible regulación a través de los receptores nucleares PPAR gamma, PPAR delta, LXRy RXR. Métodos. Se incubaron enterocitos Caco-2/TC-7durante 24 h con concentraciones (..) (AU)
Background. Several transporter proteins regulate intestinal cholesterol absorption. Of these proteins, NPC1L1 plays a major role to this process. Fatty acids (FA) modulate cholesterol absorption by a mechanism that remains unknown. Objectives. To evaluate the effect of saturated(SFA), monounsaturated (MUFA), and polyunsaturated (PUFA) fatty acids on the expression of NPC1L1 in human entrecotes (..) (AU)
Subject(s)
Fatty Acids/analysis , Fatty Acids/metabolism , Intestinal Absorption/physiology , Cholesterol/analysis , Cholesterol/metabolism , Blotting, Western/methods , Intestinal Absorption , Carrier Proteins/analysis , Carrier Proteins/blood , Enterocytes/pathologyABSTRACT
It has been suggested that the short-chain fatty acids (SCFAs) produced by anaerobic bacterial intestinal fermentation of soluble fiber may regulate lipid metabolism in intestine, thus reducing plasma cholesterol levels. However, the exact mechanism of action of SCFAs in lowering cholesterol levels is not fully understood. The aims of this study were to test the effects of SCFAs on gene expression in a human enterocyte cell line Caco-2/TC-7 and to validate microarray data by real-time PCR. Human Caco-2/TC-7 enterocytes were cultured on transwell filter inserts and incubated with the SCFAs acetate (Ac), propionate (Pr), and butyrate (Bu). Total RNA was then isolated for microarrays and quantitative real-time PCR analysis. Treatment of human enterocytes with Pr and Bu affects a wide variety of genes. These genes were classified according to the PANTHER classification system, and the results showed that different biological processes and metabolic pathways were modified by Pr and Bu treatment, including the intestinal cholesterol biosynthesis pathway. Differential array expression analysis showed that nine genes were downregulated in this pathway, and these results were validated by real-time PCR. This in vitro study allowed us to identify a wide variety of biological processes and metabolic pathways affected by the SCFAs tested. Importantly, our results show that the global effect of Pr and Bu is to downregulate the expression of nine key genes involved in intestinal cholesterol biosynthesis, thus possibly inhibiting this pathway.
Subject(s)
Cholesterol/biosynthesis , Down-Regulation/drug effects , Enterocytes/metabolism , Fatty Acids, Volatile/pharmacology , Gene Expression , Caco-2 Cells , Clone Cells , Dietary Fiber , Dose-Response Relationship, Drug , Gene Expression Profiling , Humans , Models, Biological , Oligonucleotide Array Sequence Analysis , RNA, Messenger/analysisABSTRACT
Introducción. La apolipoproteína (apo) A-V es clave en la regulación de los valores plasmáticos de los triglicéridos (TG) y se expresa en el hígado, donde se postula que dificulta el proceso de síntesis y/o ensamblaje de las lipoproteínas de muy baja densidad. Por esto, si participa en el proceso de formación de las lipoproteínas ricas en TG, también debería expresarse en el intestino delgado, porque en humanos es, junto al hígado, el otro órgano encargado de la biosíntesis de estas partículas. Material y métodos. Hemos analizado la expresión génica mediante rectro-transcripción de la reacción en cadena de la polimerasa (RT-PCR) a tiempo real de apo A5, apo B y MTP (genes clave en el proceso de síntesis y secreción de partículas ricas en TG, tanto en el hígado como en el intestino), y de apo C3 (otro gen importante en el metabolismo de los TG) en un modelo celular de intestino humano (células TC-7) y en muestras de hígado e intestino humanos. Resultados. La apo A5 se expresa en los ámbitos génico y proteico en el modelo de células intestinales, y al confirmar el resultado en las muestras de intestino humano hemos visto que se expresa principalmente en el duodeno y en el colon, y, por el contrario, la apo B se expresa principalmente en el duodeno, el yeyuno y el ileoceco; la proteína MTP principalmente en el duodeno y en el yeyuno, y la apo C3, en el yeyuno. Al analizar su relación con la expresión hepática, hemos visto que todos estos genes se expresan más en el hígado que en el intestino. Conclusiones. La apo A5 se expresa a valores bajos en el intestino delgado humano y está correlacionado inversamente con la expresión de los genes clave en el proceso de síntesis de lipoproteínas (AU)
Introduction. Apolipoprotein A-V is a key gene regulating plasmatic levels of TG, that is expressed in the liver where it has been postulated that affects the synthesis and/or assembly process of VLDL particles. Therefore, we hypothesise that if it is involved in TG rich lipoproteins' formation it should also be expressed in the small intestine, since in humans, together with the liver, is the other organ responsible on the biosynthesis of such particles. Material and methods. We have analysed the gene expression, using real time RT-PCR, of apo A5, apo B and MTP (key genes in the synthesis and secretion of TG rich lipoproteins in the liver and intestine), and apo C3 (another key gene regulating TG metabolism) in a cellular model of human intestine cells (TC-7) and in human liver and intestine samples. Results. We have detected apo A5 gene expression and protein expression in the intestinal cellular model, and when confirming this result in human intestine samples we have found that is mainly expressed in duodenum and colon, and on the contrary, apo B is expressed mainly in duodenum, jejunum and ileocecum, MTP mainly in duodenum and jejunum, and apo C3 in jejunum. When analysing its relation with their hepatic expression levels, we have found that all these genes are more expressed in the liver than in the intestine. Conclusions. Apo A5 is expressed at low levels in human small intestine and is inversely correlated with the expression of the key genes in the lipoproteins' synthesis and secretion process (AU)